New Pill from Merck Reduces ‘Bad’ Cholesterol by 60%

A groundbreaking pill developed by Merck has the potential to significantly change the treatment landscape for individuals with high cholesterol. The drug, named enlicitide, can reduce levels of harmful LDL cholesterol by as much as 60%, providing a promising alternative to current injectable treatments. This innovation could help prevent heart attacks and strokes without the need for injections, which have been the standard for managing cholesterol levels.

The mechanism by which enlicitide operates involves blocking a liver protein known as PCSK9, which hinders the body’s ability to remove cholesterol from the bloodstream. In a clinical trial lasting 24 weeks, which included 2,912 adults with a history of cardiovascular events or high risk for such events, participants taking enlicitide experienced a marked decrease in LDL cholesterol compared to those receiving a placebo. Notably, researchers observed no significant difference in side effects between both groups, suggesting that this oral medication could be both effective and well-tolerated.

Potential Game Changer in Cholesterol Management

Currently, the injectable PCSK9 inhibitors available, such as Repatha from Amgen and Praluent from Regeneron and Sanofi, have been effective but often come with higher costs and the inconvenience of injections. Dr. Dean Li, president of Merck Research Laboratories, emphasized the company’s commitment to keeping costs low for enlicitide, envisioning a treatment regimen as routine as taking aspirin. “The dream is to democratize PCSK9,” Li stated, highlighting the transformative potential of this new medication.

Developing a pill that effectively blocks PCSK9 has long been deemed challenging due to the complex structure of the protein, which makes it difficult for small molecules to target. After a decade of research, Merck scientists created an innovative circular peptide, approximately one-hundredth the size of an antibody, which successfully mimics the effects of injectable treatments.

Large-Scale Studies and Future Outlook

Merck is now conducting a larger-scale study involving over 14,500 participants to determine whether the cholesterol reductions achieved with enlicitide translate into fewer heart attacks, strokes, and overall mortality. The company plans to submit an application for approval to the U.S. Food and Drug Administration (FDA) in early 2026, with hopes for the drug to be available to patients by 2027.

The medical community is optimistic about this development. Dr. Christopher Cannon, a cardiologist at Brigham and Women’s Hospital in Boston, expressed enthusiasm for the potential impact of enlicitide, stating that if the results are validated, this could “be a game changer” in the field of cardiovascular health.

For further information on PCSK9 inhibitors, resources such as the Cleveland Clinic provide valuable insights into the current landscape of cholesterol treatments. The introduction of enlicitide offers hope for millions of individuals seeking more effective and less invasive options for managing their cholesterol levels and reducing their risk of cardiovascular events.